Approval · Notice of Compliance 38189 · 2026
RYLAZE: Notice of Compliance 38189
Issued August 27, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38189
- Date
- August 27, 2026
- Company
- Jazz Pharmaceuticals Ireland LimitedDublin, Dublin, Ireland
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RYLAZE | Not yet assigned | — |
Medicinal ingredients
- CRISANTASPASE, RECOMBINANT 10 MG per 0.5ML